<p>Xylometazoline is frequently employed to mitigate allergic rhinitis, nasal obstruction, and sinusitis. The current article presents a new development and validates an affordable, reliable, and low-cost fluorescence-based strategy for the xylometazoline assay. The concept of the assay relies on the labeling of xylometazoline with 4-chloro-7-nitrobenzofurazan. The labeled derivative formed under suitable conditions was monitored by adjusting the spectrofluorometer at an emission wavelength of 532.5&#xa0;nm and setting 472.6&#xa0;nm as excitation. The calibration graph was drawn by graphing derivative fluorescence against xylometazoline concentration, achieving reliable linearity within a spectrum of 20–600&#xa0;ng mL⁻<sup>1</sup>. Rigorous refinement of the procedural affecting variables was performed to get the highest peak of the derivative fluorescence. Validity of the study was asserted by meticulous adherence to ICH rules and the method showed excellent linearity (r = 0.9995) with a limit of quantification of 19.34&#xa0;ng mL⁻<sup>1</sup>. The strategy was satisfactorily utilized in the evaluation of xylometazoline in both nasal drops and spray forms. By analyzing these attributes, the insights for the effectiveness and applicability of the methodology were confirmed and provided a framework for comparing its performance against alternative approaches.</p>

错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Affordable and reliable fluorescence-based approach for xylometazoline detection in nasal preparations. Comprehensive assessment of whiteness and blueness

  • Ahmed A. Abu-hassan

摘要

Xylometazoline is frequently employed to mitigate allergic rhinitis, nasal obstruction, and sinusitis. The current article presents a new development and validates an affordable, reliable, and low-cost fluorescence-based strategy for the xylometazoline assay. The concept of the assay relies on the labeling of xylometazoline with 4-chloro-7-nitrobenzofurazan. The labeled derivative formed under suitable conditions was monitored by adjusting the spectrofluorometer at an emission wavelength of 532.5 nm and setting 472.6 nm as excitation. The calibration graph was drawn by graphing derivative fluorescence against xylometazoline concentration, achieving reliable linearity within a spectrum of 20–600 ng mL⁻1. Rigorous refinement of the procedural affecting variables was performed to get the highest peak of the derivative fluorescence. Validity of the study was asserted by meticulous adherence to ICH rules and the method showed excellent linearity (r = 0.9995) with a limit of quantification of 19.34 ng mL⁻1. The strategy was satisfactorily utilized in the evaluation of xylometazoline in both nasal drops and spray forms. By analyzing these attributes, the insights for the effectiveness and applicability of the methodology were confirmed and provided a framework for comparing its performance against alternative approaches.